Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
The fate of the abortion pill now depends on a decision by the Supreme Court.
It's a high stakes case that has sweeping implications for women's health, the pharmaceutical industry, and the FDA's power to regulate drugs in the U.S.
U.S. Judge Matthew Kacsmaryk last week suspended the FDA's approval of the medication, but the 5th Circuit Court of Appeals blocked that part of his order late Wednesday.
Though mifepristone remains approved in the U.S., the appeals court re-imposed restrictions on how the drug is used and distributed. The judges' decision effectively rolled back two decades of regulatory actions taken by the FDA.
The Biden administration has now asked the Supreme Court to block the lower court orders that would restrict access to mifepristone. A decision could come as soon as today.
If the lower court orders stand, many women across the U.S. will have trouble accessing an FDA approved medication.
And the pharmaceutical industry has warned that allowing the courts to roll back FDA actions on an approved drug will stifle research, development and investment in new medications.
Feel free to send any tips, suggestions, story ideas and data to me at spencer.kimball@nbcuni.com.
Tidak ada komentar:
Posting Komentar